first-line – Talk Bio

: BMS’ Opdivo plus Yervoy snags FDA nod as first-line treatment for certain colorectal cancer patients

2 weeks ago talkbio0Tagged Approved, Burning Mouth Syndrome, Colorectal Carcinoma, Combined, first-line, United States Food and Drug Administration, Yervoy

United States Food and Drug Administration, Approved, Burning Mouth Syndrome, Colorectal Carcinoma, Yervoy, first-line, Combined

AstraZeneca’s Calquence Gains FDA Approval as First-Line Treatment for Mantle Cell Lymphoma

3 months ago talkbio0Tagged acalabrutinib, Approved, AstraZeneca, BTK gene, Calquence, first-line, Inhibitor, Mantle cell lymphoma, United States Food and Drug Administration

AstraZeneca, Calquence, acalabrutinib, BTK inhibitor, mantle cell lymphoma, first-line treatment, FDA approval

GSK Reports Mixed Results for Jemperli/Zejula Combination in First-Line Ovarian Cancer Trial

4 months ago talkbio0Tagged Clinical Trials, first-line, Jemperli, mixed survival data, ovarian neoplasm, SmithKline Beecham, Zejula

GSK, Jemperli, Zejula, ovarian cancer, first-line treatment, mixed survival data, clinical trial results

Cardiff Oncology’s Onvansertib Shows Promising Results in First-Line RAS-Mutated Metastatic Colorectal Cancer Trial

4 months ago talkbio0Tagged Cardiff Oncology, first-line, onvansertib, ORR, Phase 2, RAS, RAS-mutated

Cardiff Oncology, Onvansertib, RAS-mutated metastatic colorectal cancer, Phase 2 CRDF-004 trial, objective response rate (ORR), first-line treatment.

European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer

5 months ago talkbio0Tagged BeiGene, Cancer Therapeutic Procedure, Commission approval, European (ethnic group), first-line, Gastroesophageal Junction Adenocarcinoma, Squamous cell carcinoma of esophagus, Stomach, Tevimbra, tislelizumab

TEVIMBRA, tislelizumab, European Commission approval, first-line treatment, esophageal squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, cancer treatment, BeiGene.

Novartis Secures FDA Approval for Scemblix as First-Line Treatment for Newly Diagnosed CML, Anticipates $3B in Peak Sales

6 months ago talkbio0Tagged Approved, first-line, Inhibitor, Myeloid Leukemia, Chronic, Novartis, Scemblix, TTLL5 gene, Tyrosine Kinase Inhibitors [MoA], United States Food and Drug Administration

Novartis, Scemblix, FDA Approval, First-Line Treatment, CML, Chronic Myeloid Leukemia, ASC4FIRST Trial, Tyrosine Kinase Inhibitors, STAMP Inhibitor

Jazz Pharmaceuticals Advances Combination Therapy for Extensive-Stage Small Cell Lung Cancer

6 months ago talkbio0Tagged atezolizumab, ES-SCLC, first-line, Jazz, lurbinectedin, Phase 3 IMforte trial, Small cell carcinoma of lung, Zepzelca

Jazz Pharmaceuticals, Zepzelca, lurbinectedin, atezolizumab, ES-SCLC, first-line maintenance therapy, small cell lung cancer, Phase 3 IMforte trial

Sarclisa Gains FDA Approval as First-Line Treatment for Newly Diagnosed Multiple Myeloma

7 months ago talkbio0Tagged Approved, Combined Modality Therapy, first-line, isatuximab, Multiple Myeloma, sanofi, Sarclisa, United States Food and Drug Administration, VRd

Sarclisa, FDA approval, first-line treatment, multiple myeloma, Sanofi, isatuximab, VRd combination therapy.

FDA Approves Keytruda for First-Line Treatment of Malignant Pleural Mesothelioma

7 months ago talkbio0Tagged 1-methyl-1-piperidinomethane sulfonate, Approved, first-line, Keytruda, Malignant - descriptor, Malignant Pleural Mesothelioma, pembrolizumab, Pharmacotherapy, United States Food and Drug Administration

Keytruda, FDA approval, malignant pleural mesothelioma, MPM, first-line treatment, chemotherapy, pembrolizumab

GSK’s Zejula Fails to Meet Overall Survival Goal in First-Line Ovarian Cancer, Combination Therapy Disappoints

7 months ago talkbio0Tagged Combined Modality Therapy, first-line, Maintenance, niraparib, ovarian neoplasm, Overall Survival, Restricted, second-line, SmithKline Beecham, United States Food and Drug Administration, Zejula

Zejula, niraparib, GSK, ovarian cancer, first-line treatment, overall survival, combination therapy, FDA, restriction, second-line maintenance